Septerna, Inc. (SEPN) Dividend History

Septerna, Inc. is a biotechnology company focused on developing innovative therapies targeting G protein-coupled receptors (GPCRs) to address unmet medical needs. The company leverages advanced research and proprietary technology platforms to discover and advance novel drugs in areas such as neuroscience, immunology, and metabolic diseases.

Dividend History

Septerna, Inc. currently does not pay dividends

Company News

  • Analysts Think These Stocks Could More Than Double in Value

    Analysts believe three healthcare stocks - Septerna Inc, Intellia Therapeutics, and Novavax - have the potential to at least double in price, although they carry varying levels of risk.

    Investing.com
    Featured Companies: NTLA NVAX
  • Is It Time to Buy the Dip in Novo Nordisk Stock?

    Novo Nordisk stock is down nearly 50% in 2025 despite a double beat in its quarterly earnings. Analysts believe the stock has significant upside, but factors like increased competition and a new executive order on drug pricing could weigh on the stock in the short term.

    Investing.com
    Featured Companies: CVS LLY
  • Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

    Kirby McInerney LLP is investigating potential claims against Septerna, Inc. (NASDAQ:SEPN) after the company announced the discontinuation of a clinical trial for its hypoparathyroidism treatment due to unexpected severe cases of elevated unconjugated bilirubin.

    GlobeNewswire Inc.
  • Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    Septerna, a clinical-stage biotechnology company, announced that its CEO will present at the upcoming J.P. Morgan Healthcare Conference. The company is pioneering a new era of GPCR-targeted drug discovery using its proprietary Native Complex Platform.

    GlobeNewswire Inc.
  • Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

    Septerna, a clinical-stage biotechnology company, reported financial results for Q3 2024 and provided an update on its GPCR drug discovery pipeline. The company's lead program, SEP-786, is in a Phase 1 trial for hypoparathyroidism, with data expected in mid-2025. Septerna also has several other GPCR-targeted programs in development for endocrinology, immunology, inflammation, and metabolic diseases.

    GlobeNewswire Inc.
Dividend data last updated 06/07/2025 04:24:40 UTC